The EHDN Newsletter is here! The 39th edition is dedicated to ethics in Huntington’s disease. Find it here. The European Huntington’s Disease (EHDN) newsletter aims to communicate the network’s activities and other developments of interest in the field of Huntington’s disease to the lay community, healthcare professionals and scientists. It appears three times a year (March 1, July…
Read more
Just before the new year, Wave Life Sciences announced that the drug in their huntingtin lowering trial, PRECISION-HD2, had successfully lowered the concentration of mutant huntingtin protein, while healthy huntingtin was left unchanged. Video below! Why is this so exciting? To put it simply: if you inherit Huntington’s disease, you have one sick gene and one healthy gene. Both genes code for a…
Read more
The 15th Annual Huntington’s Disease (HD) Therapeutics Conference was taking place in Palm Springs from February 24 to 27. Here is a summary of the third day, put together by tweets from HDBuzz. By HDBuzz and Phylis Kitema | Photo: HDBuzz Session: Huntingtin lowering The topic on the third day was Huntingtin lowering – one of the major avenues to Huntington’s…
Read more
The 15th Annual Huntington’s Disease (HD) Therapeutics Conference is currently taking place in Palm Springs. Here is a summary of the second day, put together by tweets from HDBuzz. By HDBuzz and Phylis Kitema | Photo: HDBuzz Session: Path to prevention Background: Enroll-HD, TRACK-HD & Self Enroll Enroll-HD collects data from Huntington’s disease (HD) patients whether they have symptoms…
Read more
The 15th Annual Huntington’s Disease (HD) Therapeutics Conference is currently taking place in Palm Springs. Here is a summary of the first day, put together by tweets from HDBuzz. By HDBuzz and Phylis Kitema | Photo: HDBuzz Morning session: Genotype and Phenotype The first session at the 15th annual HD Therapeutics Conference was “Genotype and Phenotype”, where the…
Read more
Photo, left to right: Svein Olaf Olsen and Astri Arnesen at the CHDI Therapeutics Conference in 2016. The 15th Annual Huntington’s Disease (HD) Therapeutics Conference was taking place in Palm Springs. Over four days, from February 24 to 27, drug development was discussed. Summary: DAY 1 | DAY 2 | DAY 3 The CHDI (Cure Huntington’s Disease Initiative) Foundation conference is a forum for drug…
Read more
In January, patient advocates visited the European Reference Network for Rare Neurological Diseases. During the meeting, they discussed how to provide better care and improve knowledge of rare diseases. From www.ern-rnd.eu | Meeting video below The aims of European Reference Network for Rare Neurological Diseases (ERN- RND) are to address the unmet needs of more…
Read more
RARE/D is a new podcast series that started on December 29. On the podcast, topics such as genome editing and health care are being discussed by a multidisciplinary team. The series are now available across many platforms including iTunes and Spotify. Find the episodes here. Behind the podcast series is the the Whitworth group consisting…
Read more
Just before the new year, Wave announced that the drug in the PRECISION-HD2 trial had successfully lowered the concentration of mutant huntingtin in the spinal fluid. By Dr Jeff Carroll | Edited by Dr Ed WildPublished January 03, 2020 at www.HDBuzz.net DNA-based drugs called antisense oligonucleotides, or ASOs, are now in multiple clinical trials in Huntington’s disease, aiming to lower production…
Read more
This Christmas, we launched the first HD Trial Finder in Europe. HD Trial Finder is a platform developed to make it easier for you to find out more about ongoing Huntington’s disease (HD) trials and studies in Europe. Right now, Huntington’s disease trials and studies are taking place all across Europe: GENERATION HD1, ENROLL-HD, PRECISION-HD1,…
Read more
